Breadcrumb
Drug Pricing
Direct-to-Consumer Advertising of Prescription Products |
AMCP supports direct-to-consumer advertising that educates the public about disease symptoms and available treatment options. AMCP discourages the use of direct-to-consumer advertising that promotes specific prescription drug products. |
Evidence-based Advertising of Pharmaceuticals 02/13/2019 Reapproved 02/21/2021 Revised |
AMCP supports federal regulatory requirements that ensure that drug product advertising contains claims supported by evidence-based research, and that such advertising does not contribute to drug misuse or unwarranted healthcare expenditures.
|
Best Price Requirements of the Medicaid Drug Rebate Program |
AMCP believes that the best price provisions of the Medicaid prescription drug rebate program, established by the Omnibus Budget Reconciliation Act of 1990 (P.L. 101-508), represents interference by the government into the competitive marketplace that has raised costs unnecessarily by preventing the commercial market from allowing true market dynamics to emerge. This pernicious market effect has been well documented by the U.S. Government Accountability Office (GAO), the Congressional Budget Office (CBO) and academic economists. AMCP strongly encourages a careful re-examination of the best price program.
|
Government Regulation of Prescription Drug Prices 04/12/2021 Revised |
AMCP believes that government regulation of prescription drug pricing could result in unintended consequences such as higher costs for patients, payers, and providers. Government-regulated prices could greatly impair the ability of managed care organizations (MCOs) to design a competitive benefit offering that integrates clinically sound, evidence-based medication choices with delivery systems and co-payment alternatives that provide beneficiaries with substantive choice. AMCP works to ensure patient access to medications at an affordable cost and supports working with elected officials and health care stakeholders to develop practical, informed, and market-based solutions to make prescription drugs more affordable and accessible.
|
Maximum Allowable Cost (MAC) Pricing |
AMCP believes that government regulation of prescription drug pricing, regardless of its structure, would have an overall negative impact on consumer cost, quality, and access to health care benefits. Legislation that allows the government to dictate reimbursement terms of a private contract between a payer and a pharmacy or that mandates that the payer disclose proprietary pricing methodology is not an appropriate focus of government regulation. Further, AMCP believes that competitive negotiations between parties are more likely to provide fair and equitable reimbursement on drugs dispensed. AMCP does not support the intervention of government into private contracts to require payers to advise pharmacies on where to purchase their drugs; that is an unnecessary and inappropriate intrusion into the private arrangements of a pharmacy with its supplier. This type of government mandate takes away the incentive for a pharmacy to make wise purchasing decisions. The payers and consumers will not benefit from a system of government mandated payments to a private entity; rather it will decrease competition and further drive up the cost of the prescription drug benefit.
|
Transparency Within Health Care
06/01/2011 Introduced 02/21/2021 Revised |
Appropriate transparency throughout the health care delivery system can help all parties involved – including managed care organizations, pharmacy benefit managers, payers, providers, and patients – make informed decisions regarding the use of valuable health care resources. These decisions can help promote positive health outcomes protect patient safety and ensure the affordability of a prescription drug benefit. While certain information should remain confidential to ensure a competitive marketplace, AMCP supports efforts to promote transparency throughout the entire health care system.
(See AMCP Where We Stand Position Statement – Transparency Within Health Care) |
Co-payment Offset Programs
02/01/2013 Introduced |
AMCP is supportive of programs that help patients afford their prescription drugs. However, some programs can needlessly encourage the use of more expensive brand-name products over their generic counterparts. They can also undermine the formulary development process by encouraging the use of products that have lower cost therapeutic alternatives. Patient safety can also be threatened when prescriptions are frequently transferred between retail pharmacies. Therefore, AMCP is opposed to manufacturer coupon programs that are promotional in nature and are not means-tested.
(See AMCP Where We Stand Position Statement – Co-Payment Offset Program) |
The Competitive Model
02/01/2013 Introduced |
The Academy of Managed Care Pharmacy (AMCP) supports the continuation of the competitive model for the Medicare Part D program. The Academy supports legislation and regulation that will allow proven private sector best practices to be applied in the public sector. The Academy will oppose changes to the drug benefit program that would undermine the use of effective managed care strategies. It will oppose changes that would dilute the competitive structure currently being used for the delivery of the Medicare drug benefit. Additionally, program elements that hinder the use of pharmacy benefit best practices from the private sector should be eliminated.
(See AMCP Medicare Part D Concept Series – The Competitive Model) |
Value Based Contracts
Policy 1801
04/23/2018 Introduced
|
AMCP supports the development of value-based contracts (VBCs) as an innovative means of shifting health care payment models from focusing on volume to focusing on value. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers. VBCs have emerged as a mechanism that payers may use to better align their contracting structures with broader changes in the overall health care system. A value-based contract is a written contractual agreement in which the payment terms for medication(s) or other health care technologies are tied to agreed-upon clinical circumstances, patient outcomes, or measures. AMCP is committed to advocating for legislative and regulatory changes when necessary to address barriers to the optimal execution of VBCs. |